{
  "id": 4714468,
  "title": "Quest Diagnostics SVP & general counsel sells $5.5m in shares",
  "url": "https://urgent.news/2026/08/31/quest-diagnostics-svp-general-counsel-sells-5-5m-in-shares",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-08-31T21:01:07.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/quest-diagnostics-svp--general-counsel-sells-55m-in-shares-93CH-4883288"
  },
  "original_language": "en",
  "account": null,
  "summary": "Quest Diagnostics' Senior Vice President and General Counsel, Michael E. Prevoznik, sold 22,677 shares of the company's common stock for approximately $5.51 million on August 28, 2026. The sale, which was executed under a pre-arranged Rule 10b5-1 trading plan, took place in multiple transactions at prices ranging from $242.270 to $245.247 per share, near the stock's 52-week high. Prior to the sale, Prevoznik had acquired the same number of shares by exercising non-qualified stock options, which had vested over three annual periods. Despite these transactions, Prevoznik still holds a total of 36,557 shares of Quest Diagnostics common stock, both directly and indirectly. Quest Diagnostics recently reported strong second-quarter earnings, surpassing Wall Street expectations with an adjusted earnings per share of $3.12 and revenue of $3.04 billion. The company has also raised its full-year outlook, and Truist Securities raised its price target for the stock to $250.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}